Demographic and clinical characteristics of patients at time of lymphodepleting chemotherapy
| Characteristics . | Patients (n = 47) . |
|---|---|
| Age, median (range), y | 65 (31-82) |
| Male sex, no. (%) | 31 (66) |
| ECOG performance status >1, no. (%) | 4 (9) |
| Disease stage III or IV, no. (%) | 42 (89) |
| Histology, no. (%) | |
| DLBCL NOS | 38 (81) |
| tFL | 5 (11) |
| THRLBCL | 2 (4) |
| PMBL | 1 (2) |
| HGBL | 1 (2) |
| No. of prior therapies, median (range)∗ | 3 (2-9) |
| Previous ASCT, no. (%) | 9 (19) |
| Bulky disease (>5 cm), no. (%) | 17 (36) |
| CRP ≥30 mg/L, no. (%)† | 18 (39) |
| LDH ≥2 × ULN, no. (%) | 27 (57) |
| CAR T-cell therapy, no. (%) | |
| Axi-cel | 22 (47) |
| Tisa-cel | 20 (42) |
| Liso-cel | 5 (11) |
| Time from the last BsAb dose to leukapheresis, median (range), d | 51 (13-512) |
| Time from the last BsAb dose to CAR T-cell infusion, median (range), d | 97 (47-572) |
| Time from leukapheresis to CAR T-cell infusion, median (range), d | 43 (34-103) |
| Bridging therapy, no. (%) | 42 (89) |
| Immunochemotherapy | 29 (62) |
| Targeted therapy | 9 (19) |
| Radiotherapy | 3 (6) |
| Not specified | 1 (2) |
| Response to bridging, no. (%)‡ | |
| Responder (CR/PR) | 11 (28) |
| Nonresponder (SD/PD) | 28 (72) |
| Prior BsAb exposure | |
| Type of BsAb, no. (%)§ | |
| CD20/CD3 | 43 (91) |
| CD22/CD3 | 4 (9) |
| Combination with BsAb, no. (%) | 5 (11) |
| Lenalidomide | 2 (4) |
| Chemotherapy | 2 (4) |
| Polatuzumab vedotin | 1 (2) |
| Missing | 1 (2) |
| Characteristics . | Patients (n = 47) . |
|---|---|
| Age, median (range), y | 65 (31-82) |
| Male sex, no. (%) | 31 (66) |
| ECOG performance status >1, no. (%) | 4 (9) |
| Disease stage III or IV, no. (%) | 42 (89) |
| Histology, no. (%) | |
| DLBCL NOS | 38 (81) |
| tFL | 5 (11) |
| THRLBCL | 2 (4) |
| PMBL | 1 (2) |
| HGBL | 1 (2) |
| No. of prior therapies, median (range)∗ | 3 (2-9) |
| Previous ASCT, no. (%) | 9 (19) |
| Bulky disease (>5 cm), no. (%) | 17 (36) |
| CRP ≥30 mg/L, no. (%)† | 18 (39) |
| LDH ≥2 × ULN, no. (%) | 27 (57) |
| CAR T-cell therapy, no. (%) | |
| Axi-cel | 22 (47) |
| Tisa-cel | 20 (42) |
| Liso-cel | 5 (11) |
| Time from the last BsAb dose to leukapheresis, median (range), d | 51 (13-512) |
| Time from the last BsAb dose to CAR T-cell infusion, median (range), d | 97 (47-572) |
| Time from leukapheresis to CAR T-cell infusion, median (range), d | 43 (34-103) |
| Bridging therapy, no. (%) | 42 (89) |
| Immunochemotherapy | 29 (62) |
| Targeted therapy | 9 (19) |
| Radiotherapy | 3 (6) |
| Not specified | 1 (2) |
| Response to bridging, no. (%)‡ | |
| Responder (CR/PR) | 11 (28) |
| Nonresponder (SD/PD) | 28 (72) |
| Prior BsAb exposure | |
| Type of BsAb, no. (%)§ | |
| CD20/CD3 | 43 (91) |
| CD22/CD3 | 4 (9) |
| Combination with BsAb, no. (%) | 5 (11) |
| Lenalidomide | 2 (4) |
| Chemotherapy | 2 (4) |
| Polatuzumab vedotin | 1 (2) |
| Missing | 1 (2) |
ASCT, autologous stem cell transplant; Axi-cel, axicabtagene ciloleucel; CR, complete response; CRP, C-reactive protein; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; HGBL, high-grade B-cell lymphoma; LDH, lactate dehydrogenase; Liso-cel, lisocabtagene maraleucel; NOS, not otherwise specified; PD, progressive disease; PMBL, primary mediastinal B-cell lymphoma; PR, partial response; SD, stable disease; tFL, transformed follicular lymphoma; THRLBCL, T-cell histiocyte-rich large B-cell lymphoma; Tisa-cel, tisagenlecleucel; ULN, upper limit of normal.
The median number of prior lines of therapy before BsAbs was 2 (range, 1-6).
Missing data for 1 patient.
Evaluable response in 39 patients (3 patients with missing data).
The CD20/CD3 bispecifics (n = 43/47) included glofitamab (n = 23), epcoritamab (n = 3), mosunetuzumab (n = 8), odronextamab (n = 6), and plamotamab (n = 3).